BCL2 and Miyoshi myopathy: S63845 has demonstrated the ability to augment Bcl-2 inhibition; nevertheless, KS18’s extensive synergy with both chemotherapeutics and corticosteroids indicates a more adaptable function in the treatment of refractory MM.